Literature DB >> 22451194

Refining endpoints in brain tumor clinical trials.

Christina A Meyers1, Edwin P Rock, Howard A Fine.   

Abstract

As targeted therapies advance treatment for brain tumors, standard clinical trial endpoints of survival, progression free survival and radiographic response have become insufficient to capture clinical benefit. Brain cancer is a malignancy with neurodegenerative features. In this setting prolongation of life and/or radiographic stability are less clinically meaningful if neurocognitive function substantially declines. Hence evaluation of new therapeutic strategies should routinely include periodic assessment of neurocognitive function.

Entities:  

Mesh：

Year:  2012        PMID： 22451194     DOI： 10.1007/s11060-012-0813-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  11 in total

1.  Cognitive function as a predictor of survival in patients with recurrent malignant glioma.

Authors:  C A Meyers; K R Hess; W K Yung; V A Levin
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

2.  The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity.

Authors:  Christina A Meyers; Jeffrey S Wefel
Journal:  J Clin Oncol       Date:  2003-08-11       Impact factor: 44.544

3.  Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.

Authors:  Jeffrey S Wefel; Timothy Cloughesy; James L Zazzali; Maoxia Zheng; Michael Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Asha Das; Henry S Friedman
Journal:  Neuro Oncol       Date:  2011-05-09       Impact factor: 12.300

4.  Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression.

Authors:  Christina A Meyers; Kenneth R Hess
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

5.  International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer.

Authors:  Jeffrey S Wefel; Janette Vardy; Tim Ahles; Sanne B Schagen
Journal:  Lancet Oncol       Date:  2011-02-25       Impact factor: 41.316

6.  Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma.

Authors:  Paul D Brown; Ashley W Jensen; Sara J Felten; Karla V Ballman; Paul L Schaefer; Kurt A Jaeckle; Jane H Cerhan; Jan C Buckner
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

7.  Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer.

Authors:  Aaron H Wolfson; Kyounghwa Bae; Ritsuko Komaki; Christina Meyers; Benjamin Movsas; Cecile Le Pechoux; Maria Werner-Wasik; Gregory M M Videtic; Yolanda I Garces; Hak Choy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-26       Impact factor: 7.038

Review 8.  Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines.

Authors:  D D Correa; L Maron; H Harder; M Klein; C L Armstrong; P Calabrese; J E C Bromberg; L E Abrey; T T Batchelor; D Schiff
Journal:  Ann Oncol       Date:  2007-02-06       Impact factor: 32.976

9.  Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

Authors:  Christina A Meyers; Jennifer A Smith; Andrea Bezjak; Minesh P Mehta; James Liebmann; Tim Illidge; Ian Kunkler; Jean-Michel Caudrelier; Peter D Eisenberg; Jacobus Meerwaldt; Ross Siemers; Christian Carrie; Laurie E Gaspar; Walter Curran; See-Chun Phan; Richard A Miller; Markus F Renschler
Journal:  J Clin Oncol       Date:  2004-01-01       Impact factor: 44.544

Review 10.  Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors.

Authors:  Christina A Meyers; Paul D Brown
Journal:  J Clin Oncol       Date:  2006-03-10       Impact factor: 44.544
View more
  18 in total

1.  Neurocognitive function and quality of life in patients with newly diagnosed brain metastasis after treatment with intra-operative cesium-131 brachytherapy: a prospective trial.

Authors:  Anthony Pham; Menachem Z Yondorf; Bhupesh Parashar; Ronald J Scheff; Susan C Pannullo; Rohan Ramakrishna; Philip E Stieg; Theodore H Schwartz; A Gabriella Wernicke
Journal:  J Neurooncol       Date:  2015-12-09       Impact factor: 4.130

2.  Quantitative Imaging Biomarkers of Damage to Critical Memory Regions Are Associated With Post-Radiation Therapy Memory Performance in Brain Tumor Patients.

Authors:  Kathryn R Tringale; Tanya T Nguyen; Roshan Karunamuni; Tyler Seibert; Minh-Phuong Huynh-Le; Michael Connor; Vitali Moiseenko; Mary Kay Gorman; Anisa Marshall; Michelle Devereux Tibbs; Nikdokht Farid; Daniel Simpson; Parag Sanghvi; Carrie R McDonald; Jona A Hattangadi-Gluth
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-08-10       Impact factor: 7.038

3.  Culturally and linguistically diverse patient participation in glioma research.

Authors:  Zarnie Lwin; Alexander Broom; Rasha Cosman; Ann Livingstone; Kate Sawkins; Phillip Good; Emma Kirby; Eng-Siew Koh; Elizabeth Hovey
Journal:  Neurooncol Pract       Date:  2014-06-25

Review 4.  Whole brain radiotherapy: Consequences for personalized medicine.

Authors:  Tomáš Kazda; Petr Pospíšil; Hana Doleželová; Radim Jančálek; Pavel Slampa
Journal:  Rep Pract Oncol Radiother       Date:  2013-04-19

5.  Measuring clinical benefit: use of patient-reported outcomes (PRO) in primary brain tumor clinical trials.

Authors:  Terri S Armstrong
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

6.  Cognitive impairment in primary brain tumors outpatients: a prospective cross-sectional survey.

Authors:  Chiara Zucchella; Michelangelo Bartolo; Cherubino Di Lorenzo; Veronica Villani; Andrea Pace
Journal:  J Neurooncol       Date:  2013-02-16       Impact factor: 4.130

Review 7.  Stereotactic radiosurgery for treatment of brain metastases. A report of the DEGRO Working Group on Stereotactic Radiotherapy.

Authors:  Martin Kocher; Andrea Wittig; Marc Dieter Piroth; Harald Treuer; Heinrich Seegenschmiedt; Maximilian Ruge; Anca-Ligia Grosu; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2014-04-09       Impact factor: 3.621

8.  Cognitive rehabilitation for early post-surgery inpatients affected by primary brain tumor: a randomized, controlled trial.

Authors:  Chiara Zucchella; Annarita Capone; Valentina Codella; Alessandro Marco De Nunzio; Carmine Vecchione; Giorgio Sandrini; Andrea Pace; Francesco Pierelli; Michelangelo Bartolo
Journal:  J Neurooncol       Date:  2013-05-16       Impact factor: 4.130

9.  Cognitive screening in patients with intracranial tumors: validation of the BCSE.

Authors:  Juliane Becker; Elisabeth Steinmann; Maria Könemann; Sonja Gabske; Hubertus Maximilian Mehdorn; Michael Synowitz; Gesa Hartwigsen; Simone Goebel
Journal:  J Neurooncol       Date:  2016-02-01       Impact factor: 4.130

10.  Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Martin J B Taphoorn; Linda Dirven; Andrew A Kanner; Gitit Lavy-Shahaf; Uri Weinberg; Sophie Taillibert; Steven A Toms; Jerome Honnorat; Thomas C Chen; Jan Sroubek; Carlos David; Ahmed Idbaih; Jacob C Easaw; Chae-Yong Kim; Jordi Bruna; Andreas F Hottinger; Yvonne Kew; Patrick Roth; Rajiv Desai; John L Villano; Eilon D Kirson; Zvi Ram; Roger Stupp
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.